Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

NexGel, Inc Common Stock

NXGL

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.

Last trade $3.90
Day change -$0.03 (-0.76%)
Day range $3.54 – $4.02
Volume 9,114
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.11M
Price / earnings
—
Price / book
0.43×
Price / sales
0.17×
EV / sales
0.42×
EV / EBITDA
-1.19×

Profitability

Earnings per share
-$11.54
Return on assets
-23.39%
Return on equity
-124.97%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.69×
Current ratio
0.43×
Quick ratio
0.27×
Cash ratio
0.03×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$3.34M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NXGL, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$3.69M$2.65M$2.8M$2.93M$2.88M$2.81M$3.04M$2.94M
Cost of revenue$2.58M$1.59M$1.98M$1.69M$1.63M$1.62M$1.97M$1.79M
Gross profit$1.11M$1.06M$819K$1.24M$1.26M$1.19M$1.07M$1.16M
Selling, general and administrative$3.59M$2.02M$2.04M$1.96M$1.89M$1.96M$1.92M$1.94M
Research and development$20K$0-$6K$7K$0$1K$0$0
Total operating expenses$3.61M$2.02M$2.03M$1.97M$1.89M$1.97M$1.92M$1.94M
Operating income-$2.51M-$958K-$1.21M-$725K-$636K-$777K-$841K-$788K
Interest expense-$2.23M-$42K-$34K$0-$21K-$21K-$81K$0
Income before taxes-$3.61M-$871K-$928K-$647K-$640K-$678K-$824K-$754K
Income taxes$0$0$0$0$0$0$0$0
Net income-$3.61M-$871K-$928K-$647K-$640K-$678K-$824K-$754K
Net income attributable to common shareholders-$3.64M-$927K-$970K-$653K-$665K-$712K-$850K-$693K
EBITDA-$1.68M-$859K-$1.1M-$612K-$525K-$663K-$733K-$604K
Basic earnings per share-$8.00-$2.20-$2.38-$1.60-$1.80-$1.80-$2.35-$2.20
Diluted earnings per share-$8.00-$2.20-$2.38-$1.60-$1.80-$1.80-$2.35-$2.20

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Microbot Medical Inc. (MBOT) Reports Q3 Loss, Misses Revenue Estimates

Microbot Medical reported a Q3 loss of $0.09 per share, missing the consensus estimate of $0.08 loss by 12.5%. The company posted revenues of $0.07 million, missing estimates by 71.2%. The stock has declined 48.5% year-to-date and received a Zacks Rank #4 (Sell) rating with unfavorable estimate revisions.

Zacks Investment Research

Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates

Idexx Laboratories reported Q3 2026 earnings of $3.98 per share, beating consensus estimates of $3.71, with revenues of $1.21 billion exceeding expectations. Despite consistent earnings beats over four quarters, the stock has declined 18.5% year-to-date versus the S&P 500's 10.7% gain. The company holds a Zacks Rank #2 (Buy) rating with favorable estimate revision trends, though near-term performance will depend on management guidance.

Benzinga

EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue

NexGel (NASDAQ: NXGL) agreed to acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (NASDAQ: CELU). The transaction is expected to nearly triple NexGel's annual revenue to approximately $35 million in 2026 and make the company immediately profitable. The portfolio includes six commercial-stage products focused on tendon repair, skin grafts, and bone growth with over a decade of clinical use and existing insurance reimbursement pathways.

GlobeNewswire Inc.

NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx

NEXGEL has created a spin-off company, NexGelRx, to focus exclusively on developing prescription drug delivery solutions using its proprietary hydrogel technology. NEXGEL will retain a 19.99% non-dilutive equity stake and receive a 5% perpetual global royalty.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 12, 20261-for-20reverse split